Pharma Pulse 2/7/25: SCOPE Summit 2025 Coverage, Genetic Sensitivity to Stress Possibly Links to Lung Cancer & more

SCOPE Summit 2025 Panel Discussion: Balancing Innovation Options to Enable Adoption

A common theme of discussion at SCOPE Summit 2025 has been technology, but specifically, how it is being implemented by key stakeholders in a clinical trial such as sponsors and sites. An interactive panel on day 3 of the conference explored innovations in clinical research and how they are being implemented into workflows.

Genetic Sensitivity to Stress: A Possible Link to Lung Cancer Risk

Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ancestry, and a 45% higher risk in a broader group.

Hims’ Super Bowl Ad Hit for ‘Misleading’ Weight-Loss Claims

A Super Bowl ad touting Hims & Hers Health Inc.’s copycat weight-loss drugs is getting pushback from the branded drugmakers’ lobbying group, which says it’s “misleading” and potentially violates marketing rules.

GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

GoodRx announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role.

Leo Espinoza on LinkedIn

My colleague Claudius Hildebrand sat down with Pharmaceutical Executive to offer his advice for current and aspiring CEOs in biopharma.

Learn more: https://lnkd.in/gfe6HeKs

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs